The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Applications include detailed scientific rationale and supporting clinical evidence
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
The plant is expected to enhance regional supply capabilities
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
The partnership also sets the stage for broader collaboration on rare disease treatments
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
Harbour BioMed brings advanced antibody discovery platforms to the table
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
Subscribe To Our Newsletter & Stay Updated
